Exploring Real-World Data Based Financing Models For Lung Cancer Immunotherapy In The Czech Republic

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F24%3A00138357" target="_blank" >RIV/00216224:14110/24:00138357 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1017/S0266462324003702" target="_blank" >http://dx.doi.org/10.1017/S0266462324003702</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1017/S0266462324003702" target="_blank" >10.1017/S0266462324003702</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Exploring Real-World Data Based Financing Models For Lung Cancer Immunotherapy In The Czech Republic

Popis výsledku v původním jazyce

Immunotherapy is increasingly used in the treatment of metastatic lung cancer, with coverage provided by Czech public health insurance for specific indications. This study assesses the potential budgetary impact of implementing performance-based risk-sharing agreements (PBRSA) for immunotherapy. A retrospective analysis of 127 lung cancer patients treated with immunotherapy (including 42 receiving nivolumab) at the Masaryk Memorial Cancer Institute revealed discrepancies between real-world progression-free survival (PFS) and clinical trial data. Treatment costs varied significantly based on treatment success, with unsuccessful cases averaging EUR9,300 per patient and successful cases exceeding EUR29,700. A PBRSA model could shift up to 66% of costs for unsuccessful treatments to manufacturers, potentially funding additional patients. This study highlights the importance of PBRSA in addressing the economic challenges of high-cost therapies, improving affordability, and ensuring sustainable access for patients.

Název v anglickém jazyce

Exploring Real-World Data Based Financing Models For Lung Cancer Immunotherapy In The Czech Republic

Popis výsledku anglicky

Immunotherapy is increasingly used in the treatment of metastatic lung cancer, with coverage provided by Czech public health insurance for specific indications. This study assesses the potential budgetary impact of implementing performance-based risk-sharing agreements (PBRSA) for immunotherapy. A retrospective analysis of 127 lung cancer patients treated with immunotherapy (including 42 receiving nivolumab) at the Masaryk Memorial Cancer Institute revealed discrepancies between real-world progression-free survival (PFS) and clinical trial data. Treatment costs varied significantly based on treatment success, with unsuccessful cases averaging EUR9,300 per patient and successful cases exceeding EUR29,700. A PBRSA model could shift up to 66% of costs for unsuccessful treatments to manufacturers, potentially funding additional patients. This study highlights the importance of PBRSA in addressing the economic challenges of high-cost therapies, improving affordability, and ensuring sustainable access for patients.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/LM2023049" target="_blank" >LM2023049: Český národní uzel Evropské sítě infrastruktur klinického výzkumu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů